Fortrea Earnings Call: Margins Rise Amid Revenue Pressure

Fortrea Holdings Inc. ((FTRE)) has held its Q1 earnings call. Read on for the main highlights of the call.

Fortrea Holdings’ latest earnings call struck a cautiously optimistic tone, as management emphasized strong operational progress and improving profitability despite near-term revenue and cash flow pressures. Executives highlighted rising bookings, margin expansion and cost savings as evidence that the turnaround is gaining traction, even as they acknowledged headwinds from pricing, pass-through revenue and customer concentration.

Improved Commercial Traction and Book-to-Bill Momentum

Fortrea underscored improving commercial execution, with a Q1 book-to-bill ratio of 1.15x and a trailing 12-month figure of 1.05x, marking a third straight quarter at or above 1.1x. Management pointed to new biotech wins and a healthier pipeline as signs that the sales engine is gaining momentum and should support growth as these awards convert into revenue.

Revenue Scale and Backlog Support Multi-Year Growth

First-quarter revenue came in at $636.5 million, backed by a sizable $7.8 billion backlog that provides multi-year visibility. Despite a modest top-line decline versus last year, the company reaffirmed its 2026 revenue outlook of $2.55 billion to $2.65 billion, arguing that the current backlog and recent bookings underpin confidence in the long-term growth trajectory.

Adjusted EBITDA Expansion Signals Profitability Turnaround

Profitability improved sharply, with adjusted EBITDA rising to $47 million from $30.3 million a year ago, a roughly 55% jump. Adjusted net income climbed to $15.2 million and adjusted EPS reached $0.16, which management attributed mainly to cost actions and a better project mix as Fortrea shifts toward higher-margin work.

Cash Flow and Balance Sheet Move in the Right Direction

Cash metrics, while still negative, showed substantial progress as operating cash flow improved to negative $17 million from negative $124.2 million and free cash flow to negative $25 million from negative $127.1 million. The company reported more than $0.5 billion in available liquidity and lower interest expense after debt repurchases, signaling a firmer financial footing.

Rightsizing Drives Early Cost Savings and Margin Lift

Fortrea’s rightsizing program is delivering ahead of schedule, with nearly $16 million of gross cost savings and more than $9 million of net savings in Q1 alone. These results compare with full-year targets of $70 million to $80 million gross and $40 million to $50 million net, supporting the company’s effort to steadily expand margins over the coming years.

FIT Platform Launch Targets Technology-Led Differentiation

The launch of Fortrea Intelligent Technology, an AI-enabled platform embedded in its Xcellerate suite, was a key strategic highlight. Early customer feedback has been positive, and management believes FIT can boost win rates and operational efficiency, potentially creating a technology edge in a competitive contract research market.

China and Clinical Pharmacology Show Healthy Growth

Management reported double-digit growth in China pipeline opportunities along with notable wins, underscoring the region’s growing importance in the portfolio. The Leeds clinical research unit completed first-in-human dosing for an immune thrombocytopenia program, and clinical pharmacology authorizations delivered their strongest first quarter since the unit’s founding.

Operational Execution and Quality Credentials Improve

Operationally, Fortrea cited faster site activation and start-up timelines alongside the expansion of its global site navigator program into markets such as China and Japan. The company continues to see steady gains in Net Promoter Scores, and its quality credentials were reinforced with its Chief Quality Officer elected chair of a major industry association.

Clear Path to Mid-Teens EBITDA Margins

Executives reiterated a pathway to mid-teens adjusted EBITDA margins over the next three to five years, driven by revenue diversification, growth and ongoing efficiency initiatives. Management framed Q1’s margin expansion and cost savings as early proof points that the long-term profitability plan is on track despite short-term noise.

Revenue Decline Highlights Near-Term Pressure

The quarter’s main blemish was a 2.3% year-on-year revenue decline to $636.5 million, including a 3.2% constant-currency drop partly offset by currency benefits. The shortfall was primarily tied to lower pass-through costs and lingering pressure in functional service provider, or FSP, offerings, showing that top-line recovery remains a work in progress.

FSP Pricing Concessions Weigh on Backlog Burn

Backlog burn of 8.2% in Q1 was lower than the prior quarter, partly reflecting previously disclosed pricing concessions on a large pharma FSP contract. Management noted that the reset rate card is now fully embedded in results, which depresses revenue but preserves the relationship and should provide more predictable volumes going forward.

Customer Concentration Remains a Key Risk Factor

The call highlighted ongoing customer concentration risk, with the top 10 clients contributing 54.8% of Q1 revenue and the largest single customer accounting for 17.2%. While Fortrea is working to diversify its base, investors will likely keep a close eye on how reliance on a handful of large accounts influences pricing, contract renewals and revenue volatility.

Short-Term Cash Flow Still Negative Despite Improvement

Despite major year-on-year improvement, Fortrea’s operating cash flow remained negative at $17 million and free cash flow at negative $25 million in the quarter. Management maintained its goal of becoming operating cash flow positive later in 2026, suggesting that investors should expect a gradual, rather than sudden, cash inflection.

Pass-Through Revenue and Variable Pay Create Margin Headwinds

Pass-through costs are expected to stay below 2025 levels, which supports margins but puts pressure on reported revenue throughout 2026. At the same time, variable compensation is normalizing, with about $60 million of incremental expense anticipated for the full year, representing a meaningful drag on near-term profitability despite underlying operating gains.

AI Impact and Timing Still Uncertain

While the FIT platform was welcomed by customers, management cautioned that AI-related pilots and integrations are still in the early innings. Potential productivity benefits and any influence on pricing will likely emerge over time, leaving the short-term earnings contribution from AI more of a strategic option than a near-term driver.

Guidance and Outlook Reinforce Gradual Improvement Story

Fortrea reaffirmed 2026 guidance for revenue of $2.55 billion to $2.65 billion and adjusted EBITDA of $190 million to $220 million while targeting mid-teens EBITDA margins within three to five years. The company expects a modest sequential revenue increase and a slight adjusted EBITDA step-up in Q2, underpinned by a $7.8 billion backlog, improving bookings, ongoing cost savings and a goal of turning operating cash flow positive during 2026.

Fortrea’s earnings call painted a picture of a company steadily repairing its fundamentals, combining stronger bookings, cost discipline and margin gains with a still-challenged top line and negative cash flow. For investors, the story hinges on whether management can convert a solid backlog, new technology initiatives and early savings into sustained growth and cash generation over the next several years, while managing pricing pressures and customer concentration risks.